Quoin seeks orphan drug status for QRX003 in Japan Jan 27, 2026 08:31AM
Quoin Pharmaceuticals achieves rapamycin loading targets for topical drugs Nov 11, 2025 08:31AM
Quoin Pharmaceuticals enrolls three patients in Netherton Syndrome study Oct 28, 2025 08:31AM
FDA grants orphan drug designation to Quoin's QRX003 for Netherton Syndrome Oct 21, 2025 08:30AM
Quoin Pharmaceuticals Ltd (QNRX) Misses Q2 EPS by 628c Aug 7, 2025 09:40AM


Jul 29, 2025 08:30AM QNRX advances Netherton Syndrome drug in two pivotal studies
Jun 24, 2025 08:34AM Quoin Pharmaceuticals Ltd (QNRX) Granted FDA Rare Pediatric Disease Designation for QRX003
May 22, 2025 07:31AM Quoin Pharmaceuticals Ltd (QNRX) Announces FDA Clearance to Initiate Second Pivotal Whole Body QRX003 Netherton Syndrome Clinical Study
May 14, 2025 07:30AM Quoin Pharmaceuticals (QNRX) Announces Initial Positive Clinical Data for QRX003
Apr 30, 2025 07:31AM Quoin Pharmaceuticals (QNRX) Regains Compliance with Nasdaq Minimum Bid Price Rule
Mar 25, 2025 07:31AM Quoin Pharmaceuticals Ltd (QNRX) Files U.S. Patent Application for Novel Topical Formulations to Treat Netherton Syndrome and Other Skin Diseases
Mar 4, 2025 07:30AM Quoin Pharmaceuticals (QNRX) Files U.S. and International Patent Applications for Novel Topical Rapamycin Formulations to Treat Rare Disease Indications
Feb 27, 2025 07:31AM Quoin Pharmaceuticals (QNRX) Announces Highly Positive ‘Whole Body’ Clinical Data from Ongoing Pediatric Netherton Syndrome Study
Jan 23, 2025 05:30AM Skinvisible Reports Licensee Success in Netherton Syndrome Clinical Studies
Jan 14, 2025 08:34AM Quoin Pharmaceuticals (QNRX) Announces Further Positive Clinical Data from Ongoing Pediatric Netherton Syndrome Study
Jan 6, 2025 08:33AM Quoin Pharmaceuticals (QNRX) Announces Additional Positive Interim Data from Ongoing Open-Label Netherton Syndrome Clinical Study
Dec 20, 2024 09:20AM Quoin Pharmaceuticals (QNRX) Announces Pricing of $6.8 Million Public Offering
Dec 18, 2024 08:18AM Quoin Pharmaceuticals Ltd (QNRX) Reports Positive Interim Data from Two Ongoing Netherton Syndrome Clinical Studies
Nov 5, 2024 08:02AM Quoin Pharmaceuticals (QNRX) Initiates Clinical Testing of Lead Product in Pediatric Netherton Syndrome Patient
Oct 22, 2024 08:01AM Quoin Pharmaceuticals Ltd (QNRX) Announces Further International Expansion of Ongoing Clinical Trials for Netherton Syndrome
Sep 9, 2024 08:33AM Quoin Pharmaceuticals Ltd (QNRX) Announces Insider Share Purchases by Co-Founders CEO and COO
Jun 12, 2024 08:14AM Quoin Pharmaceuticals (QNRX) Announces Signing of Research Agreement with University College Cork, Ireland